Food Science and Agriculture: Research Highlights Vol. 8

Functional foods occupy an increasingly influential but scientifically unsettled space between conventional nutrition, food technology and preventive health. The category includes naturally bioactive foods, fortified or enriched products, fermented foods, biofortified crops and food matrices engineered to deliver physiologically active compounds. This critical narrative review evaluates how convincingly such foods prevent disease, how emerging technologies are changing their design and assessment, and which scientific, regulatory and social conditions must be met for future innovation to generate public value. Literature published from 1990 to 21 May 2026 was identified through live searches of PubMed/MEDLINE and PubMed Central, supplemented by targeted scholarly web searching, citation tracking and verification through DOI and official journal landing pages. Evidence was appraised according to study design, matrix fidelity, endpoint relevance, consistency, risk of bias, generalisability and alignment between mechanistic and clinical findings.

The strongest evidence concerns functional components embedded in recognisable dietary patterns or conventional foods, particularly whole grains, viscous cereal fibres, nuts, legumes, plant sterol-fortified foods and selected fermented foods. Benefits are generally more convincing for intermediate cardiometabolic outcomes than for hard disease endpoints, and causal confidence declines when isolated compounds, short interventions, surrogate biomarkers or highly selected populations dominate the evidence. For colorectal cancer prevention, fibre-rich whole foods are supported more consistently than concentrated phytochemical supplements. Probiotic, prebiotic and fermented-food effects remain product-, strain-, substrate- and host-specific. Food-matrix structure, processing, dose, background diet and inter-individual metabolism frequently determine whether biochemical potential becomes human benefit.

Foodomics, artificial intelligence, non-thermal processing, encapsulation, nano-delivery, precision fermentation, genome editing and three-dimensional food printing may improve discovery, stability, bioavailability and personalisation. Yet most technology-centred evidence remains upstream of clinical validation, while safety assessment, interoperability, transparent algorithms, affordability, cultural fit and regulatory substantiation lag behind technical capability. Future progress requires a shift from ingredient-centred novelty towards matrix-aware, clinically anchored and equity-sensitive innovation. Functional foods can contribute to disease prevention, but they should complement rather than displace high-quality dietary patterns and structural policies that improve access to nutritious foods.